Corindus Brings In Boston Scientific Exec To Head Sales
This article was originally published in Clinica
Executive Summary
Corindus Vascular Robotics, Inc. has named Gary Lickovitch Vice President of Sales and Service. The appointment was announced Oct. 6, a day after the company said it has secured US FDA clearance for its CorPath robotic system for percutaneous coronary interventions. Lickovitch joins from Boston Scientific, where he was Area Vice-President for the Interventional Cardiology Division and was responsible for sales execution and strategy. He has also held other sales roles at Abbott Vascular and CR Bard. Corindus claims CorPath is the first device of its kind to get US regulatory approval. The robotically-assisted system allows interventional cardiologist to advance stents and guidewires with millimetre-by-millimeter precision; as the cardiologist is performing the procedure behind a console, without the need to wear lead protective equipment, they have more comfort and freedom.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.